Senescent Immune Cells Drive Immunotherapy Resistance in Cancer Through SASP-Mediated Tumor Microenvironment Remodeling

The accumulation of senescent immune cells within the tumor microenvironment represents a critical barrier to effective cancer immunotherapy, creating a self-perpetuating cycle of immune dysfunction that undermines treatment efficacy across multiple therapeutic modalities.

Senescent Immune Cells Reshape the Tumor Microenvironment

Immune cell senescence in cancer occurs through three primary mechanisms: intrinsic aging-related processes, therapy-induced damage from chemotherapy and radiotherapy, and tumor microenvironment stress including hypoxia, nutrient deprivation, and chronic inflammatory exposure. These senescent cells are characterized by irreversible cell cycle arrest, impaired effector functions, and the secretion of senescence-associated secretory phenotype (SASP) factors.

Senescent T cells, particularly CD45RA+ effector memory T cells re-expressing CD45RA (TEMRA cells), show reduced expression of co-stimulatory molecules CD27 and CD28 (search)Search target, along with increased levels of senescence markers including CD57 (search)Search target, killer cell lectin-like receptor G1 (KLRG-1 (search)Search target), and senescence-associated β-galactosidase. These cells exhibit diminished cytotoxic capacity through reduced perforin and granzyme B expression.

The SASP consists of diverse bioactive molecules including pro-inflammatory cytokines such as IL-1β, IL-6View drug details, and tumor necrosis factor alpha, chemokines like CCL2 and CXCL8, growth factors including vascular endothelial growth factor, and matrix metalloproteinases. These factors act through autocrine and paracrine mechanisms to recruit regulatory T cells and myeloid-derived suppressor cells while promoting M2 macrophage polarization.

Mechanisms of Immunotherapy Resistance

Clinical studies demonstrate that immune checkpoint inhibitors show limited efficacy in patients aged ≥75 years compared to chemotherapy, with elevated levels of circulating CD57 (search)Search target+KLRG-1 (search)Search target+ CD8+ T cells associated with poor responses to immune checkpoint blockade in non-small cell lung cancer. In aged mouse models of melanoma, reduced anti-PD-L1 (search)Search target efficacy results from impaired dendritic cell migration and diminished CD8+ T cell responses.

Senescent regulatory T cells and myeloid-derived suppressor cells accumulate in the tumor microenvironment and suppress CD8+ T cells via IL-10, TGF-β (search)Search target, PD-1 (search)Search target/PD-L1 (search)Search target, and TIGIT/CD155 signaling pathways, contributing to anti-PD-L1 therapy resistance. Metabolic dysfunction in senescent immune cells leads to upregulation of indoleamine 2,3-dioxygenase activity, resulting in L-tryptophan depletion and accumulation of immunosuppressive metabolites.

In adoptive cell therapy, senescent immune cells can impair the function of transferred cells and reduce treatment efficacy. Melanoma models demonstrate that senescent immune cells diminish CAR-T cell efficacy, while preconditioning T cells to mitigate senescence-associated phenotypes can improve the specificity and durability of adoptive cell therapy.

Therapeutic Strategies Targeting Senescence

Combination approaches integrating senolytic agents with immunotherapy show promising preclinical results. The Bcl-2 inhibitor ABT-263View drug details combined with immunotherapy enhances therapeutic efficacy by clearing senescent cells and restoring immune homeostasis within the tumor microenvironment, ultimately improving survival outcomes.

Metformin demonstrates anti-aging and anti-tumor properties by inhibiting mitochondrial complex I and mTOR (search)Search target signaling, thereby lowering systemic glucose utilization, enhancing CD8+ T cell-mediated tumor clearance, and improving anti-PD-1 (search)Search target immune checkpoint blockade efficacy. By suppressing glycolytic metabolism, metformin facilitates memory T cell development, strengthening long-term anti-tumor immunity.

Engineered CAR-T cells targeting senescent cell-specific surface markers represent an innovative approach. Urokinase-type plasminogen activator receptor (uPAR), commonly upregulated on senescent cells, has been exploited for uPAR-specific CAR-T cell therapies to selectively eliminate senescent cells, leading to improved outcomes in mouse models of lung cancer and liver fibrosis.

Advanced Biomarker Development

The absence of robust, specific, and sensitive biomarkers to accurately monitor immune senescence within the tumor microenvironment remains a major challenge. High-dimensional technologies including single-cell RNA sequencing, multiplex imaging, and spatial profiling provide opportunities to address this gap.

Spatially resolved tools such as tissue-based cyclic immunofluorescence, imaging mass cytometry, and CO-Detection by indEXing enable detailed analysis of the spatial distribution and heterogeneity of senescent immune cells across different tumor types and patient populations. Recent single-cell transcriptomic studies incorporating T cell receptor sequencing have identified Granzyme K+ CD8+ T cells as a conserved marker of inflammatory senescence.

Nanodelivery Systems for Precision Targeting

Nanodelivery systems offer promising solutions for enhancing drug targeting, stability, and bioavailability while minimizing systemic toxicity. Mesoporous polydopamine nanoparticles coated with galactan and loaded with dasatinib and quercetin can respond to high β-galactosidase activity and acidic pH, effectively clearing chemotherapy-induced senescent cells and suppressing breast cancer progression and metastasis.

Magnetic nanoparticles loaded with sulfamethazine and cloaked with platelet membranes induce ferroptosis in tumor cells while reprogramming M2-like macrophages into M1-like phenotypes, thereby disrupting the immunosuppressive tumor microenvironment and enhancing immune checkpoint inhibitor efficacy.

Clinical Implications and Future Directions

The integration of senescence-targeted therapeutics with established immunotherapies represents a promising direction for next-generation precision oncology. However, the timing of senescence-targeting intervention is critical, as interventions introduced too early may disrupt therapy-induced tumor suppression, while delayed application may allow irreversible SASP-mediated damage to accumulate.

Advanced age is a known risk factor for immune-related adverse events from immune checkpoint inhibitors, with frail older adults experiencing higher rates of hospitalization and treatment discontinuation. Despite the increasing use of immune checkpoint inhibitors in clinical practice, elderly individuals remain underrepresented in clinical trials, limiting available safety and efficacy data for this population.

The development of strategies that prevent or reverse immune cell senescence in the tumor microenvironment is essential to optimize therapeutic efficacy. By assessing immune senescence status, tumor microenvironment characteristics, and tumor mutational burden, clinicians can refine patient stratification and optimize the timing and composition of immunotherapeutic regimens.